VIBE: Evaluation of Ibandronate Efficacy - Original Investigation
PDF

Diğer

VIBE: Evaluation of Ibandronate Efficacy - Original Investigation

Turk J Osteoporos 2008;14(3)
,
PDF
İzin

VIBE Study

The VIBE (EValuation of IBandronate Efficacy) study was a retrospective study of women ≥45 years taking once monthly BONVIVA 150mg (345) or weekly alendronate 35mg/70mg (865) or risedronate 35mg (972). The study used eligibility, pharmacy claims and medical claims from research databases in the US. There are important differences in the treatment and management of osteoporosis in the US and Europe, so to create a population that was more reflective of bisphosphonate labels in Europe, the following were excluded:• patients with osteopenia • glucocorticoid use • alendronate 35mgHere we present the results of the analysis of this osteoporotic sub-group which included 41,858 patients (876).